Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET
Company Participants
Shai Biran – Senior Director Investor Relations
Esther Rajavelu – Interim Chief Executive Officer, Chief Financial Officer
Tim Keutzer – Chief Operating Officer
Conference Call Participants
Gavin Clarke-Gartner – Evercore ISI
Athena Chin – TD Cowen
Operator
Good afternoon, and welcome to the Spero Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in listen-only-mode. Following the company’s formal remarks, we will open up the call for questions. Please be advised that this call is being recorded, and a replay will be available. You can find information on the replay and further information related to today’s announcement on the Spero Therapeutics website at www. sperotherapeutics.com.
At this time, I would like to turn the call over to Shai Biran, Senior Director, Investor Relations. Mr. Biran, please go ahead.
Shai Biran
Thank you, operator, and thank you all for participating in today’s conference call. This afternoon, Spero Therapeutics released financial results and provided a business update for the fourth quarter and full year 2024. The press release is available on the Investor page of the Spero Therapeutics website.
Before we begin, I would like to remind you that some of the information presented on this conference call contains forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our actual clinical programs, future results, progress, timing, performances or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties associated with our business and factors that could cause or contribute to such differences are described in detail in Spero Therapeutics’ filings with the SEC, including in the Risk Factors section of its earnings report on Form 10-K for the year ended December 31, 2024, filed
Read the full article here
